Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P. Jerusalem G, et al. Among authors: martin m. Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358383 Free article. Clinical Trial.
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Ciruelos E, Jerusalem G, Martin M, Tjan-Heijnen VCG, Neven P, Gavila J, Montemurro F, Generali D, Lang I, Martínez-Serrano MJ, Perelló MF, Conte P. Ciruelos E, et al. Among authors: martin m. Clin Transl Oncol. 2020 Oct;22(10):1857-1866. doi: 10.1007/s12094-020-02327-5. Epub 2020 Mar 13. Clin Transl Oncol. 2020. PMID: 32170637 Clinical Trial.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Among authors: martin m. Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34102253 Free article. Clinical Trial.
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Rugo HS, et al. Among authors: martin m. Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012. Ann Oncol. 2018. PMID: 29360932 Free PMC article. Clinical Trial.
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csöszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Huang Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M. Martin M, et al. Ann Oncol. 2021 Apr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. Epub 2020 Dec 29. Ann Oncol. 2021. PMID: 33385521 Free article. Clinical Trial.
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Among authors: martin m. Ann Oncol. 2021 Oct;32(10):1307. doi: 10.1016/j.annonc.2021.07.011. Epub 2021 Aug 16. Ann Oncol. 2021. PMID: 34412950 Free article. No abstract available.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Harbeck N, et al. Among authors: martin m. Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Free article. Clinical Trial.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching PA. Jerusalem G, et al. Among authors: martin m. Clin Breast Cancer. 2022 Jun;22(4):326-335. doi: 10.1016/j.clbc.2021.12.008. Epub 2021 Dec 20. Clin Breast Cancer. 2022. PMID: 35034858 Clinical Trial.
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA. Martin M, et al. Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6. Ann Oncol. 2016. PMID: 27052654 Free article. Clinical Trial.
[Hormone therapy for breast cancer].
Lifrange E, Andre C, Bleret V, Collignon J, Coucke P, Cusumano P, Desreux J, Herman P, Jerusalem G, Kridelka F, Martin M, Rorive A, Van Cauwenberge JR, Colin C. Lifrange E, et al. Among authors: martin m. Rev Med Liege. 2011 May-Jun;66(5-6):367-71. Rev Med Liege. 2011. PMID: 21826978 Free article. French.
12,481 results
You have reached the last available page of results. Please see the User Guide for more information.